Dell falls as soft current quarter guide offsets Q2 beat, full-year outlook lift
Lexicon Pharmaceuticals , Inc. (NASDAQ:LXRX) announced Monday that it has regained compliance with the minimum $1 bid price requirement for its common stock on The Nasdaq Global Select Market. The company reported that it received a letter from Nasdaq’s Listing Qualifications staff on July 23 confirming the compliance and stating that the matter regarding its previous failure to meet the requirement is now closed.
The information is based on a press release statement included in a recent SEC filing. Investors anticipating Lexicon’s next earnings report on August 6 can access additional insights through InvestingPro, which offers 12 more exclusive tips and comprehensive analysis in the Pro Research Report, helping investors make informed decisions about this biotech company.
In other recent news, Lexicon Pharmaceuticals reported its Q1 2025 earnings, which showed a smaller-than-expected loss per share but a significant drop in revenue compared to forecasts. The company posted an EPS of -$0.07, surpassing the projected -$0.12. However, revenue reached only $1.26 million, falling short of the anticipated $2.82 million. Despite the EPS beat, the revenue shortfall has raised investor concerns. Additionally, Lexicon Pharmaceuticals announced it has received an extension from Nasdaq to regain compliance with the minimum $1 bid price requirement for its common stock. The company now has until December 30, 2025, to meet this requirement. This extension was granted after Lexicon applied to transfer its common stock listing to the Nasdaq Capital Market, a move approved by Nasdaq. These developments highlight ongoing challenges and adjustments within the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.